trending Market Intelligence /marketintelligence/en/news-insights/trending/qUPQqexWR4TpvOiZccwUvw2 content esgSubNav
In This List

EMA accepts Titan's opioid-dependence treatment for review

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


EMA accepts Titan's opioid-dependence treatment for review

Titan Pharmaceuticals Inc. said the European Medicines Agency accepted the company's marketing authorization application for Probuphine for review.

Probuphine is a substitution treatment for opioid drug dependence.

The drug is available in the U.S. as the only six-month treatment for opioid dependence that delivers buprenorphine continuously.